⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38424 | 1.00 | — | — | |
| SCHEMBL38189 | 1.00 | — | — | |
| SCHEMBL7773055 | 0.72 | — | — | |
| SCHEMBL7773061 | 0.72 | — | — | |
| SCHEMBL2401883 | 0.72 | — | — | |
| SCHEMBL1015919 | 0.72 | — | — | |
| SCHEMBL18827794 | 0.72 | — | — | |
| SCHEMBL2029625 | 0.72 | — | — | |
| SCHEMBL14231329 | 0.72 | — | — | |
| SCHEMBL11574645 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230053411-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-02-23 | — | — | US | disclosed |
| US-11142523-B2 | 1,3-thiazol-2-yl substituted benzamides | BAYER AKTIENGESELLSCHAFT (DE) | 2021-10-12 | — | — | US | disclosed |
| US-20210220357-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH NERVE FIBER SENSITIZATION | BAYER AKTIENGESELLSCHAFT (DE) | 2021-07-22 | — | — | US | disclosed |
| US-20210220358-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH NERVE FIBER SENSITIZATION | BAYER AKTIENGESELLSCHAFT (DE) | 2021-07-22 | — | — | US | disclosed |
| EP-3793553-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH NERVE FIBER SENSITIZATION | Bayer Aktiengesellschaft (DE) | 2021-03-24 | — | — | EP | disclosed |
| EP-3793554-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH NERVE FIBER SENSITIZATION | Bayer Aktiengesellschaft (DE) | 2021-03-24 | — | — | EP | disclosed |
| US-20200131169-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2020-04-30 | — | — | US | disclosed |
| US-10472354-B2 | 1,3-thiazol-2-yl substituted benzamides | BAYER AKTIENGESELLSCHAFT (DE) | 2019-11-12 | — | — | US | disclosed |
| US-20190185466-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2019-06-20 | — | — | US | disclosed |
| US-10202369-B2 | 1,3-thiazol-2-yl substituted benzamides | BAYER AKTIENGESELLSCHAFT (DE) | 2019-02-12 | — | — | US | disclosed |
| US-10183937-B2 | 1,3-thiazol-2-yl substituted benzamides | BAYER AKTIENGESELLSCHAFT (DE) | 2019-01-22 | — | — | US | disclosed |
| US-10174016-B2 | 1,3-thiazol-2-yl substituted benzamides | BEYER AKTIENGESELLSCHAFT (DE) | 2019-01-08 | — | — | US | disclosed |
| US-20180118731-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2018-05-03 | — | — | US | disclosed |
| US-20180093980-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | EVOTEC AG (DE) | 2018-04-05 | — | — | US | disclosed |
| US-20180072713-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | EVOTEC AG (DE) | 2018-03-15 | — | — | US | disclosed |
| EP-3230281-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | Bayer Aktiengesellschaft (DE) | 2017-10-18 | — | — | EP | disclosed |
| WO-2016091776-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | EVOTEC AG (DE) | 2016-06-16 | — | — | WO | disclosed |